Form D · Other Technology
Cirrus Therapeutics, Inc.
Cambridge, MA · CIK 0002078601
Offering snapshot reported Aug 19, 2025 · SEC filing
- Reported sold
- $6.7M Offering amount: $15.7M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Aug 4, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 19, 2025 | Initial | $6,698,321 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-555163
Source: Form D, filed Aug 19, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexandra Cantley | Director |
| Ying Kai Chan | Director, Executive, Promoter |
| Andrew Dick | Director, Promoter |
| Khoo Shih | Director |
Issuer details
Industry: Other Technology (See others in industry)
Address:
750 Main Street
Cambridge, MA, 02139
Cambridge, MA, 02139